Stada Arzneimittel AG announced last week the closing of the previously announced acquisition of Walmark a.s. from Mid Europa Partners.
This acquisition enables STADA to significantly broaden its global Branded Products portfolio with Walmark’s unique offering that includes variety of products (vitamins and minerals, children’s, women’s and men’s health, joint care, digestive and intestinal, and cough and cold).
“STADA and Walmark will create a winning portfolio for Central Europe: with STADA’s growth strategy and Walmark’s strong focus on innovation, we are further internationalising our overall business and strongly pushing towards our main goal – to become a leader in branded consumer health products and generics in Europe,” stated STADA CEO, Peter Goldschmidt.
“We look forward to adding Walmark’s high-quality Trinec manufacturing site to our global production network. Furthermore, we are even planning to produce selected STADA products in Trinec, thereby not only taking full advantage of the existing expertise but in addition using the facility’s capacity for supporting our strong volume growth” said STADA’s Chief Technology Officer Miguel Pagan Fernandez.
According to the Managing Director of Stada Romania, (Stada M&D S.R.L), Mihai Fugarevici, this market is of great importance for STADA Group. “With the acquisition of Walmark, STADA in Romania will become the country’s fastest growing pharmaceutical company. Adding Walmark’s well-known portfolio of branded products will also significantly strengthen our CHC pillar. With our strong local footprint, expanded portfolio and trusted brands, we remain committed to provide our customers with high-quality and affordable products, while putting us in excellent position to become one of the top 10 pharmaceutical companies in Romania”, said Fugarevici.
2020 is going to be a truly transformational year for Stada Romania
STADA Romania, the Romanian subsidiary of STADA Arzneimittel AG, announces the beginning of the integration process of Walmark Romania, aiming to become one of the fastest growing pharmaceutical company on the Romanian market, with a portfolio of RX and OTC products.
Stada Romania estimates an increase of more than 20% in turnover for 2019.
The increase is due to both the expansion of the product portfolio as well as the development of the team.
For 2020, STADA Romania (Stada M&D SRL) estimates a double digit growth maintaining the growth rate of the previous year. The budgeted growth is expected to come mainly from the development of the product portfolio, including the integration of 3 out of the 15 products purchased globally earlier this year by STADA Arzneimittel AG from GSK (CeTeBe, Orofar, Duofilm). In support of sales and marketing activities, STADA Romania is also running modern logistic operations that will be relocated in a new modern warehouse located in Timis county, that will function as a hub for the whole territory of Romania.
2020 is going to be a truly transformational year when Stada will become substantially stronger in Romania with focus on integrating the local operations of Walmark Romania, a transaction that took place globally at the end of 2019 and was approved locally by the Competition Council on February 19.
On November 4, 2019, STADA Arzneimittel AG announced that it had taken over Walmark a.s. from the investment fund Mid Europa Partners, pursuing in this way its objective, to be one of the largest pharmaceutical groups of generic drugs and CHC (non-prescription) products globally, to strengthen the portfolio in the Consumer Health segment and to consolidate the business on Eastern European markets.
The integration of the operations of Walmark Romania will be done gradually, during the whole year, through a detailed analysis of its performances, at local level. The analysis will include both the performance of retail products, as well as the performance of employees and their alignment with STADA integrity values and policies, as well as national logistics and distribution operations.
“This year will be a very important year for STADA Romania, with a lot of opportunities to become stronger and accelerate growth. We have a huge responsibility to integrate Walmark Romania and to align the new team of over 70 people with STADA values, to integrate GSK products present in our local market into the Stada portfolio, but also to relocate the Timis warehouse. And above all, we have the responsibility to launch new products, even innovative ones, for Romanian patients, to help them in their therapies. I am convinced, however, that the new team that will be formed, will successfully face these challenges and also, that all together, will be able to be as successful, occupying next year a leading position in the top 10 pharmaceutical companies in Romania,” stated Dr. Mihai Fugarevici, Country Manager STADA Romania.